US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US6822267B1
(en)
*
|
1997-08-20 |
2004-11-23 |
Advantest Corporation |
Signal transmission circuit, CMOS semiconductor device, and circuit board
|
DK1233958T3
(da)
|
1999-11-23 |
2011-10-17 |
Methylgene Inc |
Hæmmere af histondeacetylase
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
PE20020354A1
(es)
*
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
DE60138658D1
(de)
|
2000-09-29 |
2009-06-18 |
Topotarget Uk Ltd |
Carbaminsäurederivate enthaltend eine Amidgruppe zur Behandlung von Malaria
|
US7312247B2
(en)
*
|
2001-03-27 |
2007-12-25 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
EP2269609A3
(de)
*
|
2001-10-16 |
2012-07-11 |
Sloan-Kettering Institute for Cancer Research |
Behandlung von neurodegenerativen Erkrankungen und Gehirnkrebs mit Suberoylanilid-Hydroxyamsäure (SAHA)
|
ES2280597T3
(es)
*
|
2001-11-06 |
2007-09-16 |
Novartis Ag |
Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de histona desacetilasa.
|
RU2320331C2
(ru)
|
2002-03-04 |
2008-03-27 |
МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. |
Способ индукции конечной дифференцировки
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
ES2309313T3
(es)
|
2002-04-03 |
2008-12-16 |
Topotarget Uk Limited |
Compuestos del acido carbamico que comprenden un acoplamiento de piperacina como hdac inhibidores.
|
AU2003219595A1
(en)
|
2002-04-11 |
2003-10-27 |
In2Gen Co., Ltd. |
Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
|
US20040018968A1
(en)
*
|
2002-04-15 |
2004-01-29 |
George Sgouros |
Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
|
CN101816792A
(zh)
*
|
2002-06-10 |
2010-09-01 |
诺瓦提斯公司 |
包含埃坡霉素的组合及其药学用途
|
DE60332367D1
(de)
*
|
2002-08-20 |
2010-06-10 |
Astellas Pharma Inc |
Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
|
CN1681505A
(zh)
*
|
2002-09-13 |
2005-10-12 |
弗吉尼亚州立大学 |
用于治疗白血病的а ) N-{ 5-[ 4-( 4-甲基-哌嗪-1-基-甲基)-苯甲酰氨基]-2-甲基苯基}-4-( 3-吡啶基 ) -2-嘧啶-胺和b )组蛋白脱乙酰基酶抑制剂的组合
|
US7154002B1
(en)
|
2002-10-08 |
2006-12-26 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
US7250514B1
(en)
|
2002-10-21 |
2007-07-31 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
PE20040837A1
(es)
*
|
2002-11-19 |
2004-12-24 |
Takeda Chemical Industries Ltd |
Compuestos de amina
|
AU2003296310A1
(en)
|
2002-12-06 |
2004-06-30 |
University Of South Florida |
Histone deacetylase inhibitor enhancement of trail-induced apoptosis
|
TW200418806A
(en)
|
2003-01-13 |
2004-10-01 |
Fujisawa Pharmaceutical Co |
HDAC inhibitor
|
US7465719B2
(en)
|
2003-01-17 |
2008-12-16 |
Topotarget Uk Limited |
Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
|
AU2003900608A0
(en)
*
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
AU2003900587A0
(en)
*
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
JP4790594B2
(ja)
|
2003-02-25 |
2011-10-12 |
トポターゲット ユーケー リミテッド |
Hdacインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
|
JP2006520796A
(ja)
*
|
2003-03-17 |
2006-09-14 |
タケダ サン ディエゴ インコーポレイテッド |
ヒストンデアセチラーゼインヒビター
|
JP2006528952A
(ja)
*
|
2003-05-21 |
2006-12-28 |
ノバルティス アクチエンゲゼルシャフト |
ヒストンデアセチラーゼ阻害剤と化学療法剤の組み合わせ
|
WO2005011598A2
(en)
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
WO2005013958A1
(en)
*
|
2003-08-07 |
2005-02-17 |
Novartis Ag |
Histone deacetylase inhibitors as immunosuppressants
|
EP1653973A1
(de)
*
|
2003-08-08 |
2006-05-10 |
Novartis AG |
Kombinationen mit staurosporinen
|
ATE462426T1
(de)
|
2003-08-26 |
2010-04-15 |
Merck Hdac Res Llc |
Verwendung von saha zur behandlung von mesotheliom
|
CN102349927A
(zh)
|
2003-08-29 |
2012-02-15 |
Hdac默克研究有限责任公司 |
联合治疗癌症的方法
|
CN100455564C
(zh)
*
|
2003-09-12 |
2009-01-28 |
深圳微芯生物科技有限责任公司 |
组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
|
BRPI0414506A
(pt)
*
|
2003-09-18 |
2006-11-07 |
Novartis Ag |
combinação de um inibidor de histona desacetilase com um ligante de receptor de morte
|
EP1673349B1
(de)
*
|
2003-09-22 |
2010-06-30 |
S*Bio Pte Ltd |
Benzimidazolderivate: herstellung und pharmazeutische anwendungen
|
JP5042626B2
(ja)
|
2003-09-22 |
2012-10-03 |
エス*バイオ プライベート リミティッド |
ベンズイミダゾール誘導体:製造及び医薬適用
|
JP2007505938A
(ja)
*
|
2003-09-23 |
2007-03-15 |
ノバルティス アクチエンゲゼルシャフト |
Vegf受容体阻害剤と化学療法剤の組み合わせ
|
EP1682538A4
(de)
*
|
2003-10-27 |
2009-05-27 |
S Bio Pte Ltd |
Biarylgebundende hydroxamate: herstellung und pharmazeutische anwendungen
|
JP5107579B2
(ja)
|
2003-12-02 |
2012-12-26 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
新規の種類のヒストン脱アセチル化酵素阻害剤としてのZn2+キレートモチーフ係留短鎖脂肪酸
|
EP1541549A1
(de)
|
2003-12-12 |
2005-06-15 |
Exonhit Therapeutics S.A. |
Tricyclische Hydroxamat- und Benzamid-Derivate, Zusammensetzungen und Methoden
|
US20050137234A1
(en)
*
|
2003-12-19 |
2005-06-23 |
Syrrx, Inc. |
Histone deacetylase inhibitors
|
WO2005065681A1
(en)
*
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
|
US20050197336A1
(en)
*
|
2004-03-08 |
2005-09-08 |
Miikana Therapeutics Corporation |
Inhibitors of histone deacetylase
|
US7345043B2
(en)
*
|
2004-04-01 |
2008-03-18 |
Miikana Therapeutics |
Inhibitors of histone deacetylase
|
DK2253614T3
(da)
|
2004-04-07 |
2013-01-07 |
Novartis Ag |
IAP-inhibitorer
|
WO2006020004A2
(en)
*
|
2004-07-19 |
2006-02-23 |
Merck & Co., Inc. |
Histone deacetylase inhibitors
|
CA2576667A1
(en)
*
|
2004-08-09 |
2006-02-16 |
Astellas Pharma Inc. |
Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
|
ITMI20041869A1
(it)
|
2004-10-01 |
2005-01-01 |
Dac Srl |
Nuovi inibitori delle istone deacetilasi
|
US8242175B2
(en)
|
2004-10-01 |
2012-08-14 |
Dac S.R.L. |
Class of histone deacetylase inhibitors
|
US7235688B1
(en)
|
2004-11-04 |
2007-06-26 |
University Of Notre Dame Du Lac |
Process for preparing histone deacetylase inhibitors and intermediates thereof
|
US20070021612A1
(en)
*
|
2004-11-04 |
2007-01-25 |
University Of Notre Dame Du Lac |
Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
|
WO2006066133A2
(en)
*
|
2004-12-16 |
2006-06-22 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2006088949A1
(en)
|
2005-02-14 |
2006-08-24 |
Miikana Therapeutics, Inc. |
Fused heterocyclic compounds useful as inhibitors of histone deacetylase
|
US7666880B2
(en)
|
2005-03-21 |
2010-02-23 |
S*Bio Pte Ltd. |
Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
|
CA2937005A1
(en)
|
2005-03-22 |
2006-09-28 |
President And Fellows Of Harvard College |
Treatment of protein degradation disorders
|
GB0509223D0
(en)
*
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
GB0509225D0
(en)
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Inhibitors of enzymatic activity
|
WO2006122319A2
(en)
*
|
2005-05-11 |
2006-11-16 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
TWI365068B
(en)
|
2005-05-20 |
2012-06-01 |
Merck Sharp & Dohme |
Formulations of suberoylanilide hydroxamic acid and methods for producing same
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
WO2007011626A2
(en)
|
2005-07-14 |
2007-01-25 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2007016532A2
(en)
*
|
2005-08-02 |
2007-02-08 |
Novartis Ag |
Mutations and polymorphisms of hdac4
|
HUE028025T2
(en)
|
2005-08-03 |
2016-11-28 |
Novartis Ag |
Use of Panobinostat HDAC inhibitor to treat myeloma
|
KR20080035683A
(ko)
*
|
2005-08-10 |
2008-04-23 |
노파르티스 아게 |
데아세틸라제 억제제의 사용 방법
|
WO2007022044A2
(en)
*
|
2005-08-11 |
2007-02-22 |
Novartis Ag |
Combination of organic compounds
|
CA2620414A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Methylgene Inc. |
Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
EP2258357A3
(de)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenese mit Acetylcholinesterasehemmer
|
WO2007030454A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Novartis Ag |
Mutations and polymorphisms of hdac9
|
WO2007030455A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Novartis Ag |
Mutations and polymorphisms of hdac10
|
WO2007038073A2
(en)
*
|
2005-09-22 |
2007-04-05 |
Novartis Ag |
Mutations and polymorphisms of hdac11
|
AR058065A1
(es)
|
2005-09-27 |
2008-01-23 |
Novartis Ag |
Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
WO2007047998A2
(en)
*
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Mutations and polymorphisms of hdac2
|
EP1942882A2
(de)
*
|
2005-10-24 |
2008-07-16 |
Novartis AG |
Kombination aus histon-deacetylase-hemmern und strahlung
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
WO2007053502A2
(en)
*
|
2005-11-01 |
2007-05-10 |
Novartis Ag |
Mutations and polymorphisms of hdac5
|
WO2007058992A2
(en)
*
|
2005-11-14 |
2007-05-24 |
Novartis Ag |
Mutations and polymorphisms of hdac6
|
CA2629245C
(en)
|
2005-11-21 |
2016-07-12 |
Novartis Ag |
Neuroendocrine tumor treatment
|
US20070207950A1
(en)
*
|
2005-12-21 |
2007-09-06 |
Duke University |
Methods and compositions for regulating HDAC6 activity
|
JP2009525955A
(ja)
*
|
2006-01-13 |
2009-07-16 |
タケダ サン ディエゴ インコーポレイテッド |
ヒストンデアセチラーゼ阻害剤
|
US7750155B2
(en)
*
|
2006-02-07 |
2010-07-06 |
Astellas Pharma Inc. |
Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase
|
US8222423B2
(en)
|
2006-02-14 |
2012-07-17 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional histone deacetylase inhibitors
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
EP2606890A1
(de)
|
2006-04-05 |
2013-06-26 |
Novartis AG |
Kombinationen aus BCR-ABL/C-KIT/PDGF-R TK-Hemmern zu Krebsbehandlung
|
CN101415409B
(zh)
|
2006-04-05 |
2012-12-05 |
诺瓦提斯公司 |
用于治疗癌症的治疗剂的组合
|
EP2447360A1
(de)
|
2006-04-14 |
2012-05-02 |
Cell Signaling Technology, Inc. |
Gendefekte und Mutante ALK-Kinase in festen menschlichen Tumoren
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
US9539303B2
(en)
|
2006-04-24 |
2017-01-10 |
Celgene Corporation |
Treatment of Ras-expressing tumors
|
US20090018142A9
(en)
*
|
2006-05-02 |
2009-01-15 |
Zhengping Zhuang |
Use of phosphatases to treat tumors overexpressing N-CoR
|
CN101443002B
(zh)
|
2006-05-09 |
2012-03-21 |
诺瓦提斯公司 |
包含铁螯合剂和抗肿瘤药的组合及其用途
|
JP2009536667A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
5ht受容体介在性の神経新生
|
EP2021000A2
(de)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenese mittels angiotensin-modulation
|
US8957027B2
(en)
|
2006-06-08 |
2015-02-17 |
Celgene Corporation |
Deacetylase inhibitor therapy
|
EP2032533B8
(de)
*
|
2006-06-12 |
2013-12-11 |
Novartis AG |
Verfahren zur herstellung von n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamid und startmaterialien dafür
|
UA95289C2
(en)
*
|
2006-06-12 |
2011-07-25 |
Новартис Аг |
Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
|
EA015212B1
(ru)
*
|
2006-06-12 |
2011-06-30 |
Новартис Аг |
Соли n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
|
BRPI0713653A2
(pt)
|
2006-06-12 |
2012-10-23 |
Novartis Ag |
processo para a preparação de sais de n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil ]fenil]-2e-2propenamida
|
WO2007146716A2
(en)
*
|
2006-06-12 |
2007-12-21 |
Novartis Ag |
Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
|
KR20090023631A
(ko)
*
|
2006-06-26 |
2009-03-05 |
노파르티스 아게 |
유기 화합물
|
US7998971B2
(en)
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EP2064211B1
(de)
|
2006-09-20 |
2015-11-11 |
MEI Pharma, Inc. |
Imidazo[1,2-a]pyridinhydroxymatverbindungen, bei denen es sich um inhibitoren von histondeacetylase handelt
|
CN101516191A
(zh)
*
|
2006-09-28 |
2009-08-26 |
默克公司 |
Saha的胺碱盐和其多晶型物
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
GB0619753D0
(en)
*
|
2006-10-06 |
2006-11-15 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
CA2668070A1
(en)
|
2006-10-30 |
2008-05-08 |
Chroma Therapeutics Ltd. |
Hydroxamates as inhibitors of histone deacetylase
|
WO2008058287A1
(en)
*
|
2006-11-10 |
2008-05-15 |
Syndax Pharmaceuticals, Inc. |
COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
|
US8093220B2
(en)
*
|
2006-12-04 |
2012-01-10 |
Novartis Ag |
Combination of an HDAC inhibitor and an antimetabolite
|
JP2010513223A
(ja)
*
|
2006-12-15 |
2010-04-30 |
アステラス製薬株式会社 |
N−ヒドロキシアクリルアミド化合物
|
JP2010515740A
(ja)
*
|
2007-01-10 |
2010-05-13 |
ノバルティス アーゲー |
デアセチラーゼインヒビター製剤
|
BRPI0806365B8
(pt)
|
2007-02-06 |
2021-05-25 |
Lixte Biotechnology Holdings Inc |
composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
|
CN101626758A
(zh)
|
2007-02-15 |
2010-01-13 |
诺瓦提斯公司 |
用于治疗癌症的lbh589和其他治疗剂的组合
|
US20100056522A1
(en)
|
2007-03-28 |
2010-03-04 |
Santen Pharmaceutical Co., Ltd. |
Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitor effect as active ingredient
|
AU2008235212B2
(en)
*
|
2007-04-09 |
2014-01-16 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
EP2142190A1
(de)
*
|
2007-05-04 |
2010-01-13 |
Novartis Ag |
Verwendung von hdac-hemmern zur behandlung von magen-darm-krebs
|
US20110034531A1
(en)
*
|
2007-05-11 |
2011-02-10 |
Novartis Ag |
Use of hdac inhibitors for the treatment of melanoma
|
MX2009012624A
(es)
*
|
2007-05-30 |
2009-12-07 |
Novartis Ag |
Uso de inhibidores de desacetilasa de histona para el tratamiento de la destruccion osea.
|
US7737175B2
(en)
|
2007-06-01 |
2010-06-15 |
Duke University |
Methods and compositions for regulating HDAC4 activity
|
WO2009020565A1
(en)
*
|
2007-08-03 |
2009-02-12 |
Lixte Biotechnology, Inc. |
Use of phosphates to treat neuroblastomas and medullogastomas
|
CL2008002786A1
(es)
*
|
2007-09-20 |
2009-05-15 |
Novartis Ag |
Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
|
BRPI0816553A2
(pt)
|
2007-10-01 |
2017-07-18 |
Lixte Biotechnology Inc |
"composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
|
CN101896457A
(zh)
*
|
2007-10-22 |
2010-11-24 |
幽兰研究实验室有限公司 |
组蛋白脱乙酰基酶抑制剂
|
CN101417967A
(zh)
*
|
2007-10-26 |
2009-04-29 |
浙江海正药业股份有限公司 |
组蛋白去乙酰酶抑制剂、其组合物及其应用
|
WO2009067453A1
(en)
*
|
2007-11-19 |
2009-05-28 |
Syndax Pharmaceuticals, Inc. |
Combinations of hdac inhibitors and proteasome inhibitors
|
US20110044952A1
(en)
*
|
2007-11-27 |
2011-02-24 |
Ottawa Health Research Institute |
Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
|
US20110015158A1
(en)
|
2007-12-11 |
2011-01-20 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
ITFI20070288A1
(it)
|
2007-12-21 |
2009-06-22 |
A I L Firenze Sezione Autonoma |
Inibitori delle deacetilasi istoniche
|
EP2100879A1
(de)
*
|
2008-03-13 |
2009-09-16 |
4Sc Ag |
Neuartige N-substituierte Tetrahydroisochinolin/Isoindolin-Hydroxamsäure-Verbindungen
|
MX2010010525A
(es)
|
2008-03-24 |
2010-10-25 |
Novartis Ag |
Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida.
|
EP2260020B1
(de)
*
|
2008-03-26 |
2014-07-23 |
Novartis AG |
Auf hydroxamat basierende hemmer von deacetylasen b
|
CA2730738A1
(en)
*
|
2008-07-18 |
2010-01-21 |
Novartis Ag |
Use of hdac inhibitors for the treatment of hodgkin's disease
|
CA2731730C
(en)
|
2008-07-23 |
2017-06-13 |
President And Fellows Of Harvard College |
Deacetylase inhibitors and uses thereof
|
US8227473B2
(en)
|
2008-08-01 |
2012-07-24 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
|
WO2010014141A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Lixte Biotechnology, Inc. |
Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
|
AU2009277086B2
(en)
|
2008-08-01 |
2015-12-10 |
Lixte Biotechnology, Inc. |
Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
|
WO2010147612A1
(en)
|
2009-06-18 |
2010-12-23 |
Lixte Biotechnology, Inc. |
Methods of modulating cell regulation by inhibiting p53
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
DK2391366T3
(da)
|
2009-01-29 |
2013-01-07 |
Novartis Ag |
Substituerede benzimidazoler til behandling af astrocytomer
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
GB0903480D0
(en)
*
|
2009-02-27 |
2009-04-08 |
Chroma Therapeutics Ltd |
Enzyme Inhibitors
|
KR101168801B1
(ko)
|
2009-03-27 |
2012-07-25 |
주식회사종근당 |
신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
|
ES2473792T3
(es)
|
2009-04-03 |
2014-07-07 |
Naturewise Biotech & Medicals Corporation |
Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
|
US7994357B2
(en)
|
2009-04-03 |
2011-08-09 |
Naturewise Biotech & Medicals Corporation |
Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
|
EP2454267A2
(de)
|
2009-07-16 |
2012-05-23 |
Royal College of Surgeons in Ireland |
Metallkomplexe mit doppelter histondeacetylase-hemmender und dna-bindender aktivität
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
WO2011019393A2
(en)
|
2009-08-11 |
2011-02-17 |
President And Fellows Of Harvard College |
Class- and isoform-specific hdac inhibitors and uses thereof
|
AU2010283806A1
(en)
|
2009-08-12 |
2012-03-01 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
JP5819831B2
(ja)
|
2009-08-17 |
2015-11-24 |
インテリカイン, エルエルシー |
複素環式化合物およびそれらの使用
|
KR20120089463A
(ko)
|
2009-08-20 |
2012-08-10 |
노파르티스 아게 |
헤테로시클릭 옥심 화합물
|
IN2012DN01693A
(de)
|
2009-08-26 |
2015-06-05 |
Novartis Ag |
|
US20110053925A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Novartis Ag |
Hydroxamate-Based Inhibitors of Deacetylases
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
BR112012010519A2
(pt)
|
2009-11-04 |
2017-12-05 |
Novartis Ag |
derivados de sulfonamida heterocíclicos
|
CN102781237A
(zh)
|
2009-11-23 |
2012-11-14 |
天蓝制药公司 |
用于传递治疗剂的基于环糊精的聚合物
|
EA201200823A1
(ru)
|
2009-12-08 |
2013-02-28 |
Новартис Аг |
Гетероциклические производные сульфонамидов
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
US20130040998A1
(en)
*
|
2010-01-08 |
2013-02-14 |
Dana-Farber Cancer Institute, Inc. |
Fluorinated hdac inhibitors and uses thereof
|
CN103221047B
(zh)
|
2010-01-13 |
2014-12-17 |
坦颇罗制药股份有限公司 |
化合物和方法
|
WO2011088192A1
(en)
|
2010-01-13 |
2011-07-21 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
US8217079B2
(en)
|
2010-03-26 |
2012-07-10 |
Italfarmaco Spa |
Method for treating Philadelphia-negative myeloproliferative syndromes
|
WO2011119995A2
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc. |
Formulations and methods of use
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
EP2407164A1
(de)
|
2010-07-14 |
2012-01-18 |
Dublin Institute of Technology Intellectual Property Ltd |
Kupfer-II-Komplexe von Phenanthrolin und deren Verwendung in der Krebsbehandlung
|
WO2012025701A1
(en)
*
|
2010-08-25 |
2012-03-01 |
Chroma Therapeutics Ltd. |
Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors
|
WO2012025155A1
(en)
*
|
2010-08-26 |
2012-03-01 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases
|
KR20140011301A
(ko)
*
|
2010-08-27 |
2014-01-28 |
노파르티스 아게 |
데아세틸라제의 히드록사메이트-기반 억제제
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
WO2012080260A1
(en)
|
2010-12-13 |
2012-06-21 |
Novartis Ag |
Dimeric iap inhibitors
|
WO2012097013A1
(en)
|
2011-01-10 |
2012-07-19 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
TW201245115A
(en)
*
|
2011-01-24 |
2012-11-16 |
Chdi Foundation Inc |
Histone deacetylase inhibitors and compositions and methods of use thereof
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
MX2013010329A
(es)
|
2011-03-09 |
2014-03-12 |
Sverker Jern |
Compuestos y metodos para mejorarfibrinolisis endogena deteriorada usando inhibidores de histona deacetilasa.
|
CA2838029A1
(en)
|
2011-06-09 |
2012-12-13 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
MX344580B
(es)
|
2011-06-14 |
2016-12-20 |
Novartis Ag |
Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
EP2723740A1
(de)
|
2011-06-27 |
2014-04-30 |
Novartis AG |
Feststoffformen und salze von tetrahydro-pyrido-pyrimidin- derivaten
|
EP2755976B1
(de)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituierte 3-(chinolin-6-ylthio)-[1,2,4-]triazolo-[4,3-a-]pyradine als tyrosinkinase
|
CA2855243C
(en)
|
2011-11-11 |
2020-04-14 |
Novartis Ag |
Method of treating a proliferative disease
|
CN105708819B
(zh)
|
2011-11-23 |
2020-12-29 |
诺华股份有限公司 |
医药制剂
|
CN103130673B
(zh)
*
|
2011-11-28 |
2017-05-03 |
重庆医药工业研究院有限责任公司 |
一种阿戈美拉晶型i的制备方法
|
JP5992054B2
(ja)
|
2011-11-29 |
2016-09-14 |
ノバルティス アーゲー |
ピラゾロピロリジン化合物
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
EP2794594A1
(de)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Chinolinderivate
|
AP4055A
(en)
|
2011-12-22 |
2017-03-07 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
BR112014015308A2
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos para inibição da interação de bcl2 com contrapartes de ligação
|
CA2859873A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CA2859869A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US9126980B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
CA2859876A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
WO2013101600A1
(en)
*
|
2011-12-29 |
2013-07-04 |
Pharmacyclics, Inc. |
Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
|
CN117736134A
(zh)
|
2012-01-12 |
2024-03-22 |
耶鲁大学 |
通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
AR092790A1
(es)
*
|
2012-02-01 |
2015-05-06 |
Euro Celtique Sa |
Derivados bencimidazolicos del acido hidroxamico
|
CA2868202C
(en)
|
2012-04-03 |
2021-08-10 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
DK2861579T5
(da)
|
2012-05-15 |
2022-10-24 |
Novartis Ag |
Benzamidderivater til at hæmme aktiviteten af ABL1, ABL2 og BCR-ABL1
|
CA2871715A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
US9315489B2
(en)
|
2012-05-15 |
2016-04-19 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
CA2871332A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
US9365576B2
(en)
|
2012-05-24 |
2016-06-14 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
癌を処置するための組成物および該組成物を製造するための方法
|
TW201408628A
(zh)
|
2012-07-16 |
2014-03-01 |
Chdi Foundation Inc |
組蛋白去乙醯酶抑制劑及組成物,暨其使用之方法
|
EP2879675B1
(de)
|
2012-08-06 |
2019-11-13 |
Duke University |
Auf hsp90 gerichtete verbindungen und verfahren
|
MD20150043A2
(ro)
|
2012-10-02 |
2015-08-31 |
Epitherapeutics Aps |
Inhibitori ai histon-demetilazelor
|
EP2914254B1
(de)
|
2012-10-30 |
2020-01-08 |
MEI Pharma, Inc. |
Kombinationstherapien zur behandlung von chemoresistenten krebsen
|
CN105377288B
(zh)
|
2012-11-05 |
2019-11-15 |
达纳-法伯癌症研究所股份有限公司 |
Xbp1、cd138和cs1肽的组合物制备药物的用途
|
CN104994850A
(zh)
|
2012-11-08 |
2015-10-21 |
诺华股份有限公司 |
包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
EP2948453B1
(de)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinonverbindungen als inhibitoren der p53/mdm2-interaktion
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
EP3170811A1
(de)
|
2013-02-27 |
2017-05-24 |
Gilead Sciences, Inc. |
Ethyl pyridin-4-carboxylat-verbindung als inhibitor von histondemethylasen
|
CA2906542A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
CN105492011A
(zh)
|
2013-04-08 |
2016-04-13 |
丹尼斯·M·布朗 |
不理想给药化学化合物的治疗增效
|
CA2909160C
(en)
|
2013-04-09 |
2021-05-25 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
AU2014260605B2
(en)
|
2013-04-29 |
2016-07-14 |
Chong Kun Dang Pharmaceutical Corp. |
Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
CN105764501A
(zh)
|
2013-07-26 |
2016-07-13 |
现代化制药公司 |
改善比生群治疗效益的组合物
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015042078A2
(en)
|
2013-09-22 |
2015-03-26 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
EP3049442A4
(de)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
CN103467359B
(zh)
*
|
2013-09-27 |
2015-04-22 |
山东大学 |
一种含有吲哚的肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
CN103664734B
(zh)
*
|
2013-12-10 |
2015-09-23 |
广州康缔安生物科技有限公司 |
杂环羟肟酸类化合物及其药用组合物和应用
|
JP2016540024A
(ja)
|
2013-12-12 |
2016-12-22 |
チョン クン ダン ファーマシューティカル コーポレーション |
新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物
|
KR101685639B1
(ko)
|
2014-01-03 |
2016-12-12 |
주식회사 종근당 |
신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CA2940666C
(en)
|
2014-02-28 |
2022-08-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
US9399637B2
(en)
|
2014-03-28 |
2016-07-26 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
WO2015153498A1
(en)
|
2014-03-31 |
2015-10-08 |
Epitherapeutics, Aps |
Inhibitors of histone demethylases
|
AU2015241198A1
(en)
|
2014-04-03 |
2016-11-17 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
KR20210132233A
(ko)
|
2014-04-14 |
2021-11-03 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CA2954862A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
US11311512B2
(en)
|
2014-08-12 |
2022-04-26 |
Monash University |
Lymph directing prodrugs
|
CN107074807A
(zh)
|
2014-08-27 |
2017-08-18 |
吉利德科学公司 |
用于抑制组蛋白脱甲基酶的组合物和方法
|
EP2995630A1
(de)
|
2014-09-09 |
2016-03-16 |
Dublin Institute of Technology |
Aus ionischen Flüssigkeiten hergestellte, hybride Verbindungen und Verwendungen davon in ionenselektiven Elektroden
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
TWI788655B
(zh)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
MY190404A
(en)
|
2015-03-10 |
2022-04-21 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
CR20170420A
(es)
|
2015-03-13 |
2017-10-03 |
Forma Therapeutics Inc |
Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
|
US11420950B2
(en)
|
2015-05-22 |
2022-08-23 |
Chong Kun Dang Pharmaceutical Corp. |
Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
|
WO2017004133A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
EP3331906A1
(de)
|
2015-08-06 |
2018-06-13 |
Dana-Farber Cancer Institute, Inc. |
Einstellbarer endogener proteinabbau
|
WO2017032281A1
(zh)
*
|
2015-08-21 |
2017-03-02 |
苏州晶云药物科技有限公司 |
帕比司他乳酸盐的新晶型
|
US10023571B2
(en)
|
2015-09-02 |
2018-07-17 |
Nimbus Lakshimi, Inc. |
TYK2 inhibitors and uses thereof
|
AU2016318229A1
(en)
|
2015-09-08 |
2018-03-29 |
Monash University |
Lymph directing prodrugs
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
JP6800968B2
(ja)
|
2015-10-23 |
2020-12-16 |
ナビター ファーマシューティカルズ, インコーポレイテッド |
セストリン−gator2相互作用のモジュレーターおよびその使用
|
WO2017079267A1
(en)
|
2015-11-02 |
2017-05-11 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
ITUB20155193A1
(it)
|
2015-11-03 |
2017-05-03 |
Italfarmaco Spa |
Sospensioni orali di Givinostat fisicamente e chimicamente stabili
|
CN109069486A
(zh)
|
2015-12-14 |
2018-12-21 |
X4 制药有限公司 |
治疗癌症的方法
|
EP3389634B1
(de)
|
2015-12-14 |
2021-10-06 |
X4 Pharmaceuticals, Inc. |
Verfahren zur behandlung von krebs
|
EP3389664A4
(de)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
Koffeininhibitoren von mthfd2 und verwendungen dafür
|
SI3393468T1
(sl)
|
2015-12-22 |
2023-01-31 |
X4 Pharmaceuticals, Inc. |
Postopki za zdravljenje bolezni imunske pomanjkljivosti
|
CN105732467A
(zh)
*
|
2016-01-13 |
2016-07-06 |
深圳市康立生生物科技有限公司 |
一种panobinostat(帕比司他)的制备方法
|
PT3426243T
(pt)
|
2016-03-09 |
2021-08-19 |
Raze Therapeutics Inc |
Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
|
US11014882B2
(en)
|
2016-03-09 |
2021-05-25 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
EA201892075A1
(ru)
|
2016-03-15 |
2019-04-30 |
Оризон Дженомикс, С.А. |
Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
|
MX2018011100A
(es)
|
2016-03-15 |
2019-01-10 |
Oryzon Genomics Sa |
Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
|
JP2019510785A
(ja)
|
2016-04-08 |
2019-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
癌を処置する方法
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
EP3471726A4
(de)
|
2016-06-21 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
Cxcr4-inhibitoren und verwendungen davon
|
WO2017223243A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
US10759796B2
(en)
|
2016-06-21 |
2020-09-01 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
WO2017219083A1
(en)
*
|
2016-06-21 |
2017-12-28 |
The University Of Melbourne |
Activators of hiv latency
|
WO2018015493A1
(en)
|
2016-07-20 |
2018-01-25 |
Royal College Of Surgeons In Ireland |
Metal complexes having therapeutic applications
|
US20190209669A1
(en)
|
2016-08-23 |
2019-07-11 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
WO2018054960A1
(en)
|
2016-09-21 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
CA3040155C
(en)
|
2016-10-11 |
2024-01-16 |
Euro-Celtique S.A. |
Compound for use in the treatment of hodgkin lymphoma
|
EP3526222B1
(de)
|
2016-10-14 |
2022-08-17 |
Nimbus Lakshmi, Inc. |
Tyk2-inhibitoren und verwendungen davon
|
EP3528816A4
(de)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
Tyk2-inhibitoren und verwendungen davon
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
CA3043768A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
JP2020502238A
(ja)
|
2016-12-23 |
2020-01-23 |
バイスクルアールディー・リミテッド |
新規連結構造を有するペプチド誘導体
|
EP3565638B8
(de)
|
2017-01-06 |
2024-04-10 |
BicycleRD Limited |
Bizyklische konjugat zur behandlung von krebs
|
EP4119552A1
(de)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulierung von chimären antigenrezeptoren
|
TWI783978B
(zh)
|
2017-03-08 |
2022-11-21 |
美商林伯士拉克許米公司 |
Tyk2抑制劑、其用途及生產方法
|
EP3375778A1
(de)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidinderivate
|
EP3375784A1
(de)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridonderivate
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
JOP20180036A1
(ar)
|
2017-04-18 |
2019-01-30 |
Vifor Int Ag |
أملاح لمثبطات فروبورتين جديدة
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
CN107141244B
(zh)
*
|
2017-05-08 |
2019-11-19 |
潍坊医学院 |
吲哚丁酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
WO2019002842A1
(en)
|
2017-06-26 |
2019-01-03 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
|
JP7216705B2
(ja)
|
2017-07-28 |
2023-02-02 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用方法
|
KR101977970B1
(ko)
|
2017-08-04 |
2019-05-14 |
중원대학교 산학협력단 |
신규한 벤즈아미드계 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학 조성물
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
EP3668887A1
(de)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclische peptid-ligand-sting-konjugate und verwendungen davon
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
IL307995A
(en)
|
2017-09-22 |
2023-12-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
EP3461480A1
(de)
|
2017-09-27 |
2019-04-03 |
Onxeo |
Kombination von checkpoint-hemmern des dna-schädigungsantwort-zellzyklus und belinostat zur behandlung von krebs
|
EP3461488A1
(de)
|
2017-09-27 |
2019-04-03 |
Onxeo |
Kombination aus einem dbait-molekül und einem hdac-inhibitor zur behandlung von krebs
|
EP3700901A1
(de)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)heterocyclische verbindungen und verfahren zur verwendung davon
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
US20200276304A1
(en)
|
2017-10-24 |
2020-09-03 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
EP3710006A4
(de)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
Substituierte heteroarylverbindungen und verfahren zur verwendung
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
JP7021356B2
(ja)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ |
ピリミジン誘導体系キナーゼ阻害剤類
|
MX2020006812A
(es)
|
2017-12-26 |
2020-11-06 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
EP3737666A4
(de)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Proteinabbaumittel und verwendungen davon
|
KR20200112900A
(ko)
|
2018-01-20 |
2020-10-05 |
선샤인 레이크 파르마 컴퍼니 리미티드 |
치환된 아미노피리미딘 화합물 및 이의 사용 방법
|
KR20200115620A
(ko)
|
2018-01-29 |
2020-10-07 |
메르크 파텐트 게엠베하 |
Gcn2 억제제 및 이의 용도
|
EP3746075A4
(de)
|
2018-01-29 |
2021-09-08 |
Merck Patent GmbH |
Gcn2-inhibitoren und verwendungen davon
|
IL276608B2
(en)
|
2018-02-12 |
2024-04-01 |
Inimmune Corp |
TOLL-like receptor ligands
|
WO2019169001A1
(en)
|
2018-02-27 |
2019-09-06 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of tcr-nck interaction
|
WO2019183523A1
(en)
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
JP2021521192A
(ja)
|
2018-04-13 |
2021-08-26 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
セレブロンリガンドおよび同リガンドを含む二機能性化合物
|
CA3097774A1
(en)
|
2018-04-24 |
2019-10-31 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
ES2919572T3
(es)
|
2018-04-24 |
2022-07-27 |
Merck Patent Gmbh |
Compuestos antiproliferación y usos de los mismos
|
WO2019238817A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting rpn11
|
JP2021533181A
(ja)
|
2018-06-13 |
2021-12-02 |
アンフィスタ セラピューティクス リミテッド |
UchL5を標的化するための二機能性分子
|
WO2019238886A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting usp14
|
JP7382353B2
(ja)
|
2018-06-15 |
2023-11-16 |
ヤンセン ファーマシューティカ エヌ.ベー. |
ラパマイシン類似体およびその使用
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
CN108752255A
(zh)
*
|
2018-07-19 |
2018-11-06 |
重庆医科大学 |
一种帕比司他及其关键中间体的制备方法
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
EP3846793B1
(de)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e-inhibitoren und verwendungen davon
|
WO2020081508A1
(en)
|
2018-10-15 |
2020-04-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
CN112955459A
(zh)
|
2018-10-23 |
2021-06-11 |
拜斯科技术开发有限公司 |
双环肽配体和其用途
|
CN109574936B
(zh)
*
|
2018-11-23 |
2022-02-22 |
沈阳药科大学 |
一种具有hdac6抑制活性的异羟肟酸类化合物及其应用
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
AU2019389025A1
(en)
|
2018-11-30 |
2021-06-17 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
CN113453679A
(zh)
|
2018-12-20 |
2021-09-28 |
C4医药公司 |
靶向蛋白降解
|
EP3670659A1
(de)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarker und verwendungen bei der behandlung von viralen infektionen, entzündlichen oder krebserkrankungen
|
CN113348021A
(zh)
|
2019-01-23 |
2021-09-03 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
KR20220006139A
(ko)
|
2019-04-05 |
2022-01-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
JP2022534425A
(ja)
|
2019-05-31 |
2022-07-29 |
イケナ オンコロジー, インコーポレイテッド |
Tead阻害剤およびその使用
|
GB201913123D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
AU2020345962A1
(en)
|
2019-09-11 |
2022-03-31 |
Vincere Biosciences, Inc. |
USP30 inhibitors and uses thereof
|
GB201913124D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913121D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913122D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
EP3798250A1
(de)
|
2019-09-25 |
2021-03-31 |
University College Dublin |
Hyperverzweigte kationische polymere, die als nukleinsäureabgabevektoren für die transfektion geeignet sind
|
US20220340933A1
(en)
|
2019-09-25 |
2022-10-27 |
University College Dublin |
Nanoparticle compositions for gene therapy
|
EP4054546A4
(de)
*
|
2019-11-06 |
2023-10-18 |
Dana-Farber Cancer Institute, Inc. |
Selektive histon-deacetylase (hdac)-abbauprodukte und verfahren zur verwendung davon
|
CN115209897A
(zh)
|
2019-12-05 |
2022-10-18 |
安纳库利亚治疗公司 |
雷帕霉素类似物及其用途
|
IL293917A
(en)
|
2019-12-17 |
2022-08-01 |
Kymera Therapeutics Inc |
Iraq joints and their uses
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
TW202136240A
(zh)
|
2019-12-19 |
2021-10-01 |
美商亞文納營運公司 |
用於靶向降解雄激素受體之化合物及方法
|
CA3162502A1
(en)
|
2019-12-23 |
2021-07-01 |
Yi Zhang |
Smarca degraders and uses thereof
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
IT202000004075A1
(it)
|
2020-02-27 |
2021-08-27 |
Flamma Spa |
Processo per la preparazione di panobinostat
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
EP4121043A1
(de)
|
2020-03-19 |
2023-01-25 |
Kymera Therapeutics, Inc. |
Mdm2-degrader und verwendungen davon
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
EP4192509A1
(de)
|
2020-08-05 |
2023-06-14 |
Ellipses Pharma Ltd |
Behandlung von krebs mit einem cyclodextrinhaltigen polymer-topoisomerase-inhibitor-konjugat und einem parp-inhibitor
|
CN116234931A
(zh)
|
2020-08-17 |
2023-06-06 |
拜斯科技术开发有限公司 |
对nectin-4具有特异性的双环缀合物及其用途
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
EP4255895A1
(de)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead-hemmer und verwendungen davon
|
WO2022129925A1
(en)
|
2020-12-18 |
2022-06-23 |
Amphista Therapeutics Limited |
Novel bifunctional molecules for targeted protein degradation
|
GB202020359D0
(en)
|
2020-12-22 |
2021-02-03 |
Midatech Pharma Wales Ltd |
Pharmaceutical compositions and use thereof in combination therapy for brain cancer
|
CN116888116A
(zh)
|
2021-02-02 |
2023-10-13 |
里米诺生物科学有限公司 |
Gpr84拮抗剂和其用途
|
US20230113202A1
(en)
|
2021-02-02 |
2023-04-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023028235A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
US20230134932A1
(en)
|
2021-08-25 |
2023-05-04 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
GB2611043A
(en)
|
2021-09-22 |
2023-03-29 |
Univ Dublin City |
A cis-platinum(II)-oligomer hybrid
|
WO2023089183A1
(en)
|
2021-11-19 |
2023-05-25 |
Branca Bunus Limited |
A composition comprising a therapeutically active agent packaged within a drug delivery vehicle
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023194441A1
(en)
|
2022-04-05 |
2023-10-12 |
Istituto Nazionale Tumori Irccs - Fondazione G. Pascale |
Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
GB2617409A
(en)
|
2022-04-27 |
2023-10-11 |
Cancertain Ltd |
Method for predicting responsiveness to therapy
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
WO2023242597A1
(en)
|
2022-06-16 |
2023-12-21 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeted protein degradation
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024041744A1
(en)
|
2022-08-26 |
2024-02-29 |
Biodexa Ltd. |
Combination therapy for brain cancer
|